AbCellera Biologics (ABCL) Expected to Announce Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect AbCellera Biologics to post earnings of ($0.17) per share and revenue of $7.12 million for the quarter.

AbCellera Biologics Price Performance

NASDAQ ABCL traded down $0.08 during trading hours on Friday, reaching $2.41. The company's stock had a trading volume of 3,284,466 shares, compared to its average volume of 2,704,904. The firm has a market capitalization of $719.20 million, a price-to-earnings ratio of -3.95 and a beta of 0.46. The company's 50-day moving average is $2.38 and its two-hundred day moving average is $2.77. AbCellera Biologics has a 1-year low of $1.89 and a 1-year high of $4.34.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABCL. Stifel Nicolaus decreased their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. KeyCorp lifted their target price on shares of AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Finally, Benchmark restated a "hold" rating on shares of AbCellera Biologics in a research report on Monday, March 3rd.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.